



2016-11-02

**PRESS RELEASE**

**Nexttobe Extends Loan to Oasmia Pharmaceutical**

Uppsala, Sweden, November 2, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company and also significantly improved the interest terms.

The current loan from Nexttobe amounts to MSEK 94.4 and is due on December 31, 2016. The new loan replaces the current at due date and amounts, including the accrued interest for 2016, to MSEK 102.4 in total, and is due for payment on September 30, 2017. The interest for the new loan is set at 3.5 %.

**For more information, please contact:**

Julian Aleksov

Tel: +46 18 50 54 40

E-mail: [julian.aleksov@oasmia.com](mailto:julian.aleksov@oasmia.com)

**Notes to editors:**

**About Oasmia Pharmaceutical AB**

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

---

Information is also available at [www.oasmia.com](http://www.oasmia.com) [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com) [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de) [twitter.com/oasmia](https://twitter.com/oasmia)

*"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08.00 CET on November 2, 2016."*